Your browser is no longer supported. Please, upgrade your browser.
ENOB Enochian Biosciences Inc. daily Stock Chart
Enochian Biosciences Inc.
Index- P/E- EPS (ttm)-0.82 Insider Own0.10% Shs Outstand37.22M Perf Week-6.63%
Market Cap188.71M Forward P/E- EPS next Y- Insider Trans- Shs Float13.82M Perf Month-20.90%
Income-29.90M PEG- EPS next Q- Inst Own2.40% Short Float2.83% Perf Quarter-29.58%
Sales- P/S- EPS this Y-138.80% Inst Trans- Short Ratio10.76 Perf Half Y-19.52%
Book/sh3.88 P/B1.31 EPS next Y- ROA-17.10% Target Price- Perf Year-3.43%
Cash/sh0.28 P/C18.32 EPS next 5Y- ROE-19.90% 52W Range3.32 - 9.50 Perf YTD-27.57%
Dividend- P/FCF- EPS past 5Y-8.80% ROI- 52W High-46.63% Beta0.21
Dividend %- Quick Ratio6.90 Sales past 5Y- Gross Margin- 52W Low52.71% ATR0.52
Employees2 Current Ratio6.90 Sales Q/Q- Oper. Margin- RSI (14)35.25 Volatility8.15% 8.63%
OptionableNo Debt/Eq0.00 EPS Q/Q-6.30% Profit Margin- Rel Volume0.39 Prev Close5.43
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume36.30K Price5.07
Recom- SMA20-15.40% SMA50-16.85% SMA200-23.24% Volume14,409 Change-6.63%
Jun-03-19 07:00AM  Enochian BioSciences Inventor Named to Two Important Scientific Committees GlobeNewswire
Apr-29-19 09:19AM  Enochian Biosciences (NASDAQ:ENOB) Shareholders Have Enjoyed A 37% Share Price Gain Simply Wall St. -8.15%
Mar-07-19 12:45PM  Successful Treatment of London Patient Underscores Clinical Potential of Enochian Biosciences Gene Modified Cellular Therapy for HIV GlobeNewswire -6.88%
Feb-01-19 02:31PM  4 Healthcare Stocks Looking To Start February Off Strong ACCESSWIRE +9.88%
Jan-16-19 04:00PM  OTC Markets Group Announces Quarterly Index Performance and Rebalancing PR Newswire +10.00%
Jan-07-19 08:30AM  Enochian Biosciences Announces Appointment of Dr. Mark Dybul as Executive Vice-Chair GlobeNewswire
Jan-04-19 08:00AM  How Much Of Enochian Biosciences Inc. (NASDAQ:ENOB) Do Insiders Own? Simply Wall St.
Dec-05-18 08:30AM  Enochian Biosciences Announces Uplisting to Nasdaq Under Symbol ENOB GlobeNewswire
Dec-03-18 08:30AM  Enochian Biosciences to Present at Biotech Showcase 2019 GlobeNewswire
Enochian Biosciences Inc., a biopharmaceutical company, identifies, develops, manufactures, and commercializes gene therapies for HIV/AIDS and cancer patients. Its lead candidate include ENO-1001 a genetically modified cell therapy for patients with HIV/AIDS. It is also developing ENO-2001, an HIV vaccine; and additional compounds, such as ENO-4001, ENO-4002, ENO-3001, and ENO-5001 that are in discovery stage for prevention of relapse in colon cancer patients. Enochian BioSciences is headquartered in Los Angeles, California.